CATX Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -- compared to Perspective Therapeutics's net margin of 2.76%. Perspective Therapeutics's return on equity of -- beat InfuSystems Holdings's return on equity of 4.33%.

Perspective Therapeutics has a consensus price target of $14.39, signalling upside risk potential of 677.99%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 183.64%. Given that Perspective Therapeutics has higher upside potential than InfuSystems Holdings, analysts believe Perspective Therapeutics is more attractive than InfuSystems Holdings.

Perspective Therapeutics has a beta of 1.199, which suggesting that the stock is 19.866% more volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.898, suggesting its more volatile than the S&P 500 by 89.81%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. Perspective Therapeutics's net income of -$40.2M is lower than InfuSystems Holdings's net income of $933K. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 49.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 11.98x versus 0.80x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Perspective Therapeutics's net margin of -18.58%. Perspective Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Perspective Therapeutics has a consensus price target of $14.39, signalling upside risk potential of 677.99%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Perspective Therapeutics has higher upside potential than Retractable Technologies, analysts believe Perspective Therapeutics is more attractive than Retractable Technologies.

Perspective Therapeutics has a beta of 1.199, which suggesting that the stock is 19.866% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Perspective Therapeutics's net income of -$40.2M is lower than Retractable Technologies's net income of -$1.9M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 11.98x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Perspective Therapeutics's net margin of -1226.82%. Perspective Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

Perspective Therapeutics has a consensus price target of $14.39, signalling upside risk potential of 677.99%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 484.8%. Given that Perspective Therapeutics has higher upside potential than VolitionRX, analysts believe Perspective Therapeutics is more attractive than VolitionRX.

Perspective Therapeutics has a beta of 1.199, which suggesting that the stock is 19.866% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Perspective Therapeutics's net income of -$40.2M is lower than VolitionRX's net income of -$5.8M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 11.98x versus 35.08x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Perspective Therapeutics's net margin of -10.04%. Perspective Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Perspective Therapeutics has a consensus price target of $14.39, signalling upside risk potential of 677.99%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 343.04%. Given that Perspective Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Perspective Therapeutics is more attractive than Xtant Medical Holdings.

Perspective Therapeutics has a beta of 1.199, which suggesting that the stock is 19.866% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Perspective Therapeutics's net income of -$40.2M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 11.98x versus 0.45x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.